Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: nifurtimox
Trade Name: LAMPIT
Date Designated: 08/05/2010
Orphan Designation: Treatment of Chagas disease (American Typanosomiasis)caused by T. cruzi
Orphan Designation Status: Designated/Approved
Bayer HealthCare Pharmaceuticals, Inc.
100 BAYER BLVD
WHIPPANY, New Jersey 07981
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: nifurtimox
Trade Name: LAMPIT
Marketing Approval Date: 08/06/2020
Approved Labeled Indication: LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi
Exclusivity End Date: 08/06/2027 
Exclusivity Protected Indication* :  indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-